Vicore Pharma Holding AB
NASDAQ:VCREMedical - Pharmaceuticals
-$0.24 today
- Market cap
- $279.65M
- Beta
- 0.15
Volume 0.00M
Average 0.26M
VCRE Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Vicore Pharma Holding ABNASDAQ: VCRE
Total Equity · Q2 FY2026 · quarter ended Jun 2026
Total equity of SEK 88.04M in Q2 FY2026
Q2 FY2026 total equity was SEK 88.04M.
Context
- Total equity amounted to 91.8% of total assets at the end of Q2 FY2026.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
SEK · from the balance sheet
- Latest · FY2025
- 1.1B SEK
- Year-over-year change
- —
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.1B | — |
Total Equity vs competitors
How VCRE compares with its peers on the latest reported figures
- Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
- Total equity amounts to 91.8% of total assets for VCRE, versus a peer median of 37.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $195.11M USD | +1184.7% | -20.9% | 37.4% | |
VCREVicore Pharma Holding AB | Jun 2026 | SEK 88.04M SEK | — | — | 91.8% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding VCRE) | — | +1184.7% | -20.9% | 37.4% | |
Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Vicore Pharma Holding AB
NASDAQ:VCRE
Intrinsic Alpha fair value
Locked
Current Price
$9.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.